Epidemiology of Nontuberculous Mycobacteria in Nanjing and MAB_0540 Mutations Associated with Clofazimine Resistance in Mycobacterium abscessus

References

• Koh W-J, Schlossberg D. Nontuberculous mycobacteria-overview. Microbiol Spectr. 2017;5(1). doi:10.1128/microbiolspec.TNMI7-0024-2016
   PubMed Web of Science ®Google Scholar
• Zhou L, Xu D, Liu H, Wan K, Wang R, Yang Z. Trends in the prevalence and antibiotic resistance of non-tuberculous mycobacteria in Mainland China, 2000–2019: systematic review and meta-analysis. Front Public Health. 2020;8:295. doi:10.3389/fpubh.2020.00295
   PubMed Web of Science ®Google Scholar
• Johansen MD, Herrmann J-L, Kremer L. Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus. Nat Rev Microbiol. 2020;18(7):392–407. doi:10.1038/s41579-020-0331-1
   PubMed Web of Science ®Google Scholar
• Dahl VN, Mølhave M, Fløe A, et al. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J Infect Dis. 2022;125:S1201971222005513.
   Web of Science ®Google Scholar
• Ratnatunga CN, Lutzky VP, Kupz A, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol. 2020;11:303. doi:10.3389/fimmu.2020.00303
   PubMed Web of Science ®Google Scholar
• Shahraki AH, Heidarieh P, Bostanabad SZ, et al. “Multidrug-resistant tuberculosis” may be nontuberculous mycobacteria. Eur J Intern Med. 2015;26(4):279–284. doi:10.1016/j.ejim.2015.03.001
   PubMed Web of Science ®Google Scholar
• McCarthy KD, Cain KP, Winthrop KL, et al. Nontuberculous mycobacterial disease in patients with HIV in Southeast Asia. Am J Respir Crit Care Med. 2012;185(9):981–988. doi:10.1164/rccm.201107-1327OC
   PubMed Web of Science ®Google Scholar
• Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015;36(1):91–99. doi:10.1016/j.ccm.2014.11.002
   PubMed Web of Science ®Google Scholar
• Ahmed I, Tiberi S, Farooqi J, et al. Non-tuberculous mycobacterial infections-A neglected and emerging problem. Int J Infect Dis. 2020;92S:S46–S50. doi:10.1016/j.ijid.2020.02.022
   PubMedGoogle Scholar
• Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57(6):2003300. doi:10.1183/13993003.03300-2020
   PubMed Web of Science ®Google Scholar
• Wu M-L, Aziz DB, Dartois V, Dick T. NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018;23(8):1502–1519. doi:10.1016/j.drudis.2018.04.001
   PubMed Web of Science ®Google Scholar
• Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: current status and future perspectives. J Global Antimicrobl Resist. 2021;25:48–59. doi:10.1016/j.jgar.2021.02.017
   PubMed Web of Science ®Google Scholar
• Vesenbeckh S, Schönfeld N, Roth A, et al. Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections. Eur Respir J. 2017;49(5):1700083. doi:10.1183/13993003.00083-2017
   PubMed Web of Science ®Google Scholar
• Pfaeffle HOI, Alameer RM, Marshall MH, Houpt ER, Albon DP, Heysell SK. Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria. Pulm Pharmacol Ther. 2021;70:102058. doi:10.1016/j.pupt.2021.102058
   PubMed Web of Science ®Google Scholar
• Ye M, Xu L, Zou Y, et al. Molecular analysis of linezolid-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(2):e01842–01818. doi:10.1128/AAC.01842-18
   PubMed Web of Science ®Google Scholar
• Dupont C, Viljoen A, Thomas S, et al. Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish. Antimicrob Agents Chemother. 2017;61(11):e01225–01217. doi:10.1128/AAC.01225-17
   PubMed Web of Science ®Google Scholar
• Richard M, Gutiérrez AV, Viljoen A, et al. Mutations in the MAB_2299c TetR regulator confer cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(1):e01316–e01318. doi:10.1128/AAC.01316-18
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen J, Zhang S, et al. Novel mutations associated with clofazimine resistance in Mycobacterium abscessus. Antimicrob Agents Chemother. 2018;62(7):e00544–00518. doi:10.1128/AAC.00544-18
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xiao H, Yan L. PCR-reverse blot hybridization assay in respiratory specimens for rapid detection and differentiation of mycobacteria in HIV-negative population. BMC Infect Dis. 2021;21(1):264. doi:10.1186/s12879-021-05934-x
   PubMed Web of Science ®Google Scholar
• Woods GL, Brown-Elliott BA, Conville PS, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2011.
   Google Scholar
• Gene, National Library of Medicine (US), National Center for Biotechnology Information. 2004 . Available from: https://www.ncbi.nlm.nih.gov/gene/. Accessed May 1, 2023.
   Google Scholar
• Untergasser A, Cutcutache I, Koressaar T, et al. Primer3--new capabilities and interfaces. Nucleic Acids Research. 2012;40(15):e115. doi:10.1093/nar/gks596
   PubMed Web of Science ®Google Scholar
• Robert X, Gouet P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Research. 2014;42(W320–W324). doi:10.1093/nar/gku316
   PubMed Web of Science ®Google Scholar
• Shao Y, Chen C, Song H, et al. The epidemiology and geographic distribution of nontuberculous mycobacteria clinical isolates from sputum samples in the eastern region of China. PLoS Negl Trop Dis. 2015;9(3):e0003623. doi:10.1371/journal.pntd.0003623
   PubMed Web of Science ®Google Scholar
• Hu C, Huang L, Cai M, Wang W, Shi X, Chen W. Characterization of non-tuberculous mycobacterial pulmonary disease in Nanjing district of China. BMC Infect Dis. 2019;19(1):764. doi:10.1186/s12879-019-4412-6
   PubMed Web of Science ®Google Scholar
• Wang D-M, Liao Y, Li Q-F, et al. Drug resistance and pathogenic spectrum of patients coinfected with nontuberculous mycobacteria and human-immunodeficiency virus in Chengdu, China. Chin Med J. 2019;132(11):1293–1297. doi:10.1097/CM9.0000000000000235
   PubMed Web of Science ®Google Scholar
• Lee H, Myung W, Koh W-J, Moon SM, Jhun BW. Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007–2016. Emerg Infect Dis. 2019;25(3):569–572. doi:10.3201/eid2503.181597
   PubMed Web of Science ®Google Scholar
• Floyd K, Glaziou P, Zumla A, Raviglione M. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018;6(4):299–314. doi:10.1016/S2213-2600(18)30057-2
   PubMed Web of Science ®Google Scholar
• Tan Y, Deng Y, Yan X, et al. Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: a prospective surveillance study. J Infect. 2021;83(1):46–53. doi:10.1016/j.jinf.2021.05.019
   PubMed Web of Science ®Google Scholar
• Liu C-F, Song Y-M, He W-C, et al. Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey. Infect Dis Poverty. 2021;10(1):59. doi:10.1186/s40249-021-00844-1
   PubMed Web of Science ®Google Scholar
• Pang Y, Zheng H, Tan Y, Song Y, Zhao Y. In vitro activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother. 2017;61(5):e02627–02616. doi:10.1128/AAC.02627-16
   PubMed Web of Science ®Google Scholar
• Yu X, Gao X, Li C, et al. In vitro activities of bedaquiline and delamanid against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob Agents Chemother. 2019;63(8):e00031–00019. doi:10.1128/AAC.00031-19
   PubMed Web of Science ®Google Scholar
• Schulthess B, Akdoğan Kittana FN, Hömke R, Sander P. In vitro bedaquiline and clofazimine susceptibility testing in Mycobacterium abscessus. Antimicrob Agents Chemother. 2022;66(5):e02346–02321. doi:10.1128/aac.02346-21
   PubMed Web of Science ®Google Scholar
• Aguilar-Ayala DA, Cnockaert M, André E, et al. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol. 2017;66(8):1140–1143. doi:10.1099/jmm.0.000537
   PubMed Web of Science ®Google Scholar
• Kwak N, Whang J, Yang JS, Kim TS, Kim SA, Yim -J-J. Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome. Chest. 2021;159(2):517–523. doi:10.1016/j.chest.2020.07.040
   PubMed Web of Science ®Google Scholar
• Luo J, Yu X, Jiang G, et al. In vitro activity of clofazimine against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob Agents Chemother. 2018;62(7):e00072–00018. doi:10.1128/AAC.00072-18
   PubMed Web of Science ®Google Scholar
• Wen S, Gao X, Zhao W, et al. Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China. Int J Infect Dis. 2021;109:253–260. doi:10.1016/j.ijid.2021.06.055
   PubMed Web of Science ®Google Scholar
• Yu X, Huo F, Wang F, et al. In vitro antimicrobial activity comparison of linezolid, tedizolid, sutezolid and delpazolid against slowly growing mycobacteria isolated in Beijing, China. Infect Drug Resist. 2021;14:4689–4697. doi:10.2147/IDR.S332835
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lu J, Song Y, Pang Y. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Diagn Microbiol Infect Dis. 2018;90(1):31–34. doi:10.1016/j.diagmicrobio.2017.09.013
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim S-Y, Koh W-J, Jhun BW. In vitro activity of oxazolidinone against nontuberculous mycobacteria, including macrolide-resistant clinical isolates. Antimicrob Agents Chemother. 2021;65(7):e02306–e02320. doi:10.1128/AAC.02306-20
   PubMed Web of Science ®Google Scholar
• Kim DH, Jhun BW, Moon SM, et al. In Vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates. Antimicrob Agents Chemother. 2019;63(8):e00665–00619. doi:10.1128/AAC.00665-19
   PubMed Web of Science ®Google Scholar
• Krieger D, Schönfeld N, Vesenbeckh S, et al. Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Eur Respir J. 2016;48(6):1803–1804. doi:10.1183/13993003.01420-2016
   PubMed Web of Science ®Google Scholar
• Zheng H, Wang Y, He W, et al. In vitro activity of pretomanid against nontuberculous mycobacteria. Antimicrob Agents Chemother. 2022;66(1):e01810–e01821. doi:10.1128/AAC.01810-21
   PubMed Web of Science ®Google Scholar
• Omar SV, Ismail F, Ndjeka N, Kaniga K, Ismail NA. Bedaquiline-resistant tuberculosis associated with Rv0678 mutations. N Engl J Med. 2022;386(1):93–94. doi:10.1056/NEJMc2103049
   PubMed Web of Science ®Google Scholar
• Li B, Ye M, Guo Q, et al. Determination of MIC distribution and mechanisms of decreased susceptibility to bedaquiline among clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2018;62(7):e00175–00118. doi:10.1128/AAC.00175-18
   PubMed Web of Science ®Google Scholar
• Ruth MM, Sangen JJN, Remmers K, et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. J Antimicrob Chemother. 2019;74(4):935–943. doi:10.1093/jac/dky526
   PubMed Web of Science ®Google Scholar
• Kim S-Y, Jhun BW, Moon SM, et al. Genetic mutations in linezolid-resistant Mycobacterium avium complex and Mycobacterium abscessus clinical isolates. Diagn Microbiol Infect Dis. 2019;94(1):38–40. doi:10.1016/j.diagmicrobio.2018.10.022
   PubMed Web of Science ®Google Scholar